Issue 2/2009
Content (30 Articles)
Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells
Maiko Suzuki, Fumiaki Shinohara, Manabu Endo, Masaki Sugazaki, Seishi Echigo, Hidemi Rikiishi
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients
Pol M. Specenier, Tudor Ciuleanu, Jane E. Latz, Luna C. Musib, Christelle L. S. Darstein, Jan B. Vermorken
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
Patrick A. Thompson, Gary L. Rosner, Katherine K. Matthay, Theodore B. Moore, Lisa R. Bomgaars, Kenneth J. Ellis, Jamie Renbarger, Stacey L. Berg
Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine
William B. Parker, Sue C. Shaddix, Karen S. Gilbert, Rodney V. Shepherd, William R. Waud
Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus
Joseph Boni, Richat Abbas, Cathie Leister, Jaime Burns, Ronald Jordan, Matthew Hoffmann, William DeMaio, Bruce Hug
Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy
Kouichi Momiyama, Hidenari Nagai, Yasukiyo Sumino
Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat
Premila Abraham, Suganthy Rabi
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
Monica Mita, Alain Mita, John Sarantopoulos, Chris H. Takimoto, Eric K. Rowinsky, Ofelia Romero, Patrizia Angiuli, Cecilia Allievi, Amy Eisenfeld, Claire F. Verschraegen
Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study
Johanna Mäenpää, Arto Leminen
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer
Katia Lorizzo, Nicola Fazio, Davide Radice, Sabrina Boselli, Leonardo Ariu, Maria Giulia Zampino, Franco Nolè, Elena Magni, Raffaele Ardito, Ida Minchella, Andrea Rocca, Giovanni Di Meglio, Michela Squadroni, Filippo de Braud
Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro
Kate Connolly, Richard Mitter, Morwenna Muir, Duncan Jodrell, Sylvie Guichard
Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
Kyung Hee Lee, Min Kyoung Kim, Yeol Hong Kim, Baek Yeol Ryoo, Ho Yeong Lim, Hong Suk Song, Hoon Kyo Kim, Myung Ah Lee, Seock Ah Im, Heung Moon Chang, Jae Yong Cho, Dae Young Zang, Bong Seog Kim, Jun Suk Kim
Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma
Youling Gong, Li Ren, Lin Zhou, Jiang Zhu, Meijuan Huang, Xiaojuan Zhou, Jin Wang, You Lu, Mei Hou, Yuquan Wei
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates
Lindsay B. Kilburn, Peter L. Bonate, Susan M. Blaney, Leticia McGuffey, Jed G. Nuchtern, Robert Dauser, Patrick Thompson, Brian W. Gibson, Stacey L. Berg
Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer
Satoru Tanaka, Takehiro Nohara, Mitsuhiko Iwamoto, Kazuhiro Sumiyoshi, Kousei Kimura, Yuko Takahashi, Nobuhiko Tanigawa
A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer
Kyoung Ha Kim, Young Suk Park, Myung Hee Chang, Hyo Song Kim, Hyun Jung Jun, Jieun Uhm, Seong Yoon Yi, Do Hyoung Lim, Sang Hoon Ji, Min Jae Park, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin
Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Won Sik Lee, Chang-Hak Sohn, Joo Seop Jung, Gab Chul Kim, Ho Young Chung, Wansik Yu
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
Takanori Ishida, Takayoshi Kiba, Motohiro Takeda, Kotone Matsuyama, Satoshi Teramukai, Ryota Ishiwata, Norikazu Masuda, Yuichi Takatsuka, Shinzaburo Noguchi, Chikashi Ishioka, Masanori Fukushima, Noriaki Ohuchi
A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer
Hyun Jung Kim, Nam Su Lee, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Young Gook Cheon, Young Seok Kim, Jong Ho Moon, Young Deok Cho, Sang Heum Park, Kyu Taek Lee, Sung Kyu Park, Jong-Ho Won, Hee Sook Park, Dae Sik Hong
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma
Joaquín Casal Rubio, S. Vázquez, F. Vázquez, M. Amenedo, J. L. Fírvida, J. R. Mel, G. Huidobro, E. Álvarez, M. Lázaro, G. Alonso, I. Fernández
Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer
Gyeong-Won Lee, Myung-Hee Kang, Hoon-Gu Kim, Jung Hun Kang, Seok Hyun Kim, Yu Ji Cho, Yi Yeong Jeong, Ho-Cheol Kim, Jong Duk Lee, Young Sil Hwang, Hye Jung Kim, Jong-Seok Lee
Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
Nicolas Tsavaris, Andreas Lazaris, Christos Kosmas, Panagiotis Gouveris, Nikolaos Kavantzas, Petros Kopterides, Thomas Papathomas, George Arapogiannis, Haralambos Zorzos, Vassiliki Kyriakou, Efstathios Patsouris
Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
Nicolas Tsavaris, Andreas Lazaris, Christos Kosmas, Panagiotis Gouveris, Nikolaos Kavantzas, Petros Kopterides, Thomas Papathomas, George Agrogiannis, Haralambos Zorzos, Vassiliki Kyriakou, Efstratios Patsouris
Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
Peter Schmid, J. Krocker, R. Kreienberg, P. Klare, K. Kittel, H. Sommer, G. Heinrich, T. Steck, W. Lichtenegger, D. Elling, S. Kümmel
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer
S. H. Waters, A. Gillibrand, H. Berry, S. Kumar, G. Velikova, D. J. Dodwell, Timothy J. Perren
In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B
Khalid Abu Ajaj, Ralph Graeser, Iduna Fichtner, Felix Kratz
The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells
Alessandro Ascione, Maurizio Cianfriglia, Maria Luisa Dupuis, Alessandra Mallano, Andrea Sau, Francesca Pellizzari Tregno, Silvia Pezzola, Anna Maria Caccuri
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours
Edwina N. Scott, Anne L. Thomas, L. Rhoda Molife, Samreen Ahmed, Sarah Blagden, Peter C. Fong, Kristin Kowal, Candice McCoy, Herbert Wiesinger, Will Steward, Johann De Bono
Anthocyanins-based drugs for colon cancer treatment: the nutritionist’s point of view
Fabio Galvano, Federico Salamone, Anna Nicolosi, Paola Vitaglione